Novartis tapped MRM Worldwide, an interactive and relationship marketing company, to undertake European patient communications for its Aclasta CRM program, it was announced yesterday.
Aclasta is an annual infusion for the treatment of Paget's disease and is in the third phase of clinical trials for other metabolic bone disorders such as osteoporosis.
Novartis said it also is considering letting MRM Worldwide pitch for all of its global CRM opportunities.
MRM Partners, a unit of McCann Worldgroup, which is owned by Interpublic Group of Companies, has 62 offices in 37 countries, more than 1,700 employees and clients such as Coca-Cola, Dell, General Motors, Intel, Royal Bank of Scotland Group, Tesco, UPS, Unilever and Vodafone.
